Eliza Hawkes

Mycosis fungoides and Sezary syndrome: Australian clinical practice statement

Friyana K Bhabha, Christopher McCormack, Jillian Wells, Belinda A Campbell, Kate Newland, Stephen Lade, Odette Buelens, David Joske, Jake Shortt, Sally Mapp, Dejan Radeski, Mark Hertzberg, Amit Khot, Carrie Van der Weyden, Christine Khoo, Eliza Hawkes, H Miles Prince

Journal article  |  2021  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

Primary cutaneous lymphomas represent a heterogeneous group of T- and B-cell lymphomas with distinct clinical presentations, histo..

Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic

Zoe Loh, Eliza A Hawkes, Fiona Chionh, Arun Azad, Geoffrey Chong

Journal article  |  2021  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

BACKGROUND: Prompt and accurate diagnosis of lymphadenopathy is important, yet there is wide variability in clinical approach and ..

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine /- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Kate Manos, Masa Lasica, Andrew Grigg, Pietro R Di Ciaccio, Jonathan Wong, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K Yannakou, Nada Hamad, Gareth P Gregory, Shane A Gangatharan, Tara Cochrane, Kristen Piper, Leonid Churilov, Eliza A Hawkes

Journal article  |  2020  |  Blood

Background: Bendamustine +/- anti-CD20 antibody is a highly effective regimen for iNHL. Though initially favoured f..

Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression

Oliver A Piercey, Zoe Loh, Joanna Chan, Geoff Chong, Andrew Grigg, Steven Cheema, Gurjot Gill, Matthew Whybird, Tania Cushion, Eliza A Hawkes

Journal article  |  2020  |  JCO ONCOLOGY PRACTICE

PURPOSE: Patients with indolent non-Hodgkin lymphoma (iNHL) undergo regular active surveillance in between treatment periods to de..

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Mansi Bhurani, Lorenz Admojo, Carrie Van der Weyden, Robert Twigger, Ali Bazargan, Hang Quach, Allan Zimet, Luke Coyle, Julian Lindsay, Dejan Radeski, Eliza Hawkes, Glen Kennedy, Ian Irving, Naadir Gutta, Judith Trotman, James Yeung, Lindsay Dunlop, Minh Hua, Pratyush Giri, Sam Yuen, et al.

Journal article  |  2020  |  LEUKEMIA & LYMPHOMA

We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients wit..

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Katharine L Lewis, Collin K Chin, Kate Manos, John Casey, Nada Hamad, Julie Crawford, Shir-Jing Ho, Samar Issa, Andrew Grigg, Peter Wood, Maher K Gandhi, Bryan Do, Loretta Nastoupil, Eliza A Hawkes, Chan Y Cheah

Journal article  |  2020  |  BRITISH JOURNAL OF HAEMATOLOGY

Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encour..

Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.

Eliza Anne Hawkes, Kate Manos, Geoffrey Chong, Jodie Palmer, Michael Patrick MacManus, Colm Keane, Andrew Mark Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Anne Barraclough, Sze Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Journal article  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

TPS8075 Background: Most DLBCL & FL responds well to first line treatment, yet relapsed disease outcomes are poor. PD1/PDL1 inhib..

Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma

Melissa J Garwood, Eliza A Hawkes, Leonid Churilov, Geoffrey Chong

Journal article  |  2020  |  CANCER CHEMOTHERAPY AND PHARMACOLOGY

INTRODUCTION: Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is usually fatal. Risk stratification ..

Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study

Priscilla Gates, Karla Gough, Haryana Dhillon, Carlene Wilson, Eliza Hawkes, Vincent Dore, Yuliya Perchyonok, Christopher C Rowe, Adam K Walker, Janette L Vardy, Michiel de Ruiter, Meinir Krishnasamy

Journal article  |  2020  |  BMJ OPEN

INTRODUCTION: Cancer-related cognitive impairment (CRCI) is a distressing and disabling side-effect of cancer treatments affecting..

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

Allison Barraclough, Edward Yoo, Chan Y Cheah, Dipti Talaulikar, Bianca Nguyen, Michelle Turner, Fatima Tahir, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M Johnston, Michael Dickinson, Stephen Opat, Zoe McQuilten, Erica M Wood, Gayathri St George, Cameron Wellard, Eliza A Hawkes

Conference Proceedings  |  2019  |  BLOOD

Background The time to treatment initiation is determined by tumour burden in patients with follicular lymphoma (FL..